Yonsei University · Medicine
Professor Sung Gyun Ahn's research lab specializes in interventional cardiology and vascular biology, focusing on optimizing percutaneous coronary intervention (PCI) outcomes in acute myocardial infarction. The lab investigates mechanisms of vascular inflammation, endothelial dysfunction, and microvascular obstruction—particularly the no-reflow phenomenon—using both clinical trials and advanced imaging techniques such as intravascular ultrasound (IVUS). Key research directions include the synergistic effects of antiplatelet and anticoagulant therapies, thrombus aspiration strategies, and drug-eluting stent optimization in complex coronary lesions.
Figures are computed from collected data and may differ slightly.
Vascular endothelium, situated at the boundary between blood and tissues, is now known to play a critical role in the inflammatory process through recruiting immune cells into tissues and sites of inflammation. Lipopolysaccharide (LPS), endotoxic component extracted from the cell wall of gram-negative bacteria, stimulates endothelial cells to activate the nuclear transcription factor NF-kappaB and induce various adhesion molecules and inflammatory mediators. Among the anti-apoptotic genes activa
Combination treatment using IC abciximab and AT may synergistically improve myocardial perfusion in patients with STEMI undergoing primary PCI (Trial Registration: clinicaltrials. gov Identifier: NCT01404507).
Manual thrombus aspiration reduced no-reflow incidence in STEMI patients with LTB. However, even after thrombectomy, prestenting residual thrombi and decreased coronary flow were related to a higher occurrence of the no-reflow phenomenon.
The use of IVUS may improve the effectiveness and safety of multiple overlapping drug-eluting stenting for long, diffuse coronary lesions.
Metabolic syndrome confers an increased risk of CCVD irrespective of sexes; LDL-C > 3.4 mmol/L alone has a greater influence on CCVD occurrence in men than in women. Metabolic syndrome and high LDL-C beget a synergistically detrimental impact on the incidence of CCVD in both men and women. Treatment of dyslipidaemia and metabolic syndrome should be tailored according to patient characteristics.
Tailored antiplatelet therapy according to point-of-care genetic and phenotypic testing may be effective in decreasing HOPR after 30 days.
Loss-of-function (LoF) alleles of cytochrome P450 2C19 (CYP2C19), which are prevalent in East Asians, are linked to high platelet reactivity (HPR) phenotype and poor prognosis. We aimed to investigate the incremental predictive value of HPR combined with CYP2C19 genotype in predicting outcomes after drug-eluting stent (DES) implantation. The patients treated with platelet function and genotype-related long-term prognosis in drug-eluting stent (PTRG-DES) consortium enrolled a total of 13,160 Kore
These results suggest that poor myocardial perfusion and anterior location of myocardial infarction can affect left atrial remodeling in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. It appears that adequate myocardial perfusion is crucial to prevent left atrial remodeling, a poor prognostic factor in acute myocardial infarction.
Background and Objectives: We evaluated the effectiveness of genotype- and phenotype-directed individualization of P2Y 12 inhibitors to decrease high on-treatment platelet reactivity (HOPR). Subjects and Methods: Sixty-five patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syn -dromes were randomly assigned to genotype- or phenotype-directed treatment. All patients were screened for CYP2C19*2, *3, or *17 al-leles by using the Verigene CLO assay (Nanospher
Background and Objectives: Stented segment length is a predictive factor for restenosis and stent thrombosis still in the drug-eluting stent (DES) era, and the benefit of routine intravascular ultrasound (IVUS) is still unclear. The aim of the present study was to investigate whether IVUS-guided percutaneous coronary intervention (PCI) improved the vascular outcomes as compared with conventional PCI in the treatment of diffuse coronary artery disease. Subjects and Methods: From our registry data
Open papers in the app to read, cite, and organize with AI.